Apo E in multiple sclerosis and optic neuritis: The Apo E-ε4 allele is associated with progression of multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 5, 2005, Pages 511-515

  Pinholt, M ^a   Frederiksen, J L ^a   Andersen, P S ^b   Christiansen, M ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Apo E; Genotype; Multiple Sclerosis; Optic neuritis; Phenotype; Progression rate

Indexed keywords

APOLIPOPROTEIN E4;

ACUTE DISEASE; ADULT; ALLELE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DATA ANALYSIS; DENMARK; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE SCLEROSIS; OPTIC NERVE DISEASE; OUTPATIENT DEPARTMENT; POPULATION RESEARCH; PROSPECTIVE STUDY; RATING SCALE; STATISTICAL SIGNIFICANCE;

ADULT; AGE OF ONSET; ALLELES; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PHENOTYPE;

EID: 25844450924     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1207oa     Document Type: Article

References (39)

1. Koch-Henriksen N, Hyllested K. Epidemiology in multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry. Acta Neurol Scand 1998; 78: 369-80.
2. Sørensen TL, Frederiksen JL, Brønnum-Hansen H, Petersen HC. Optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey. Neurology 1999; 53: 473-78.
3. Baranzini SE, Oksenberg JR. Role of genomics in studying MS. Int MSJ 2001; 9/3: 91-99.
4. Siest G, Pillot T, Regis-Bailly A, Leininger-Muller B, Steinmetz J, Galteau MM, et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem 1995; 41: 1068-86.
5. Gerdes LU, Klausen IC, Sihm I, Færgeman O. Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genet Epidemiol 1992; 9: 155-67.
6. Laskowitz DT, Horsburgh K, Roses AD. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab 1998; 18: 465-71.
7. Lynch JR, Tang W, Wang H, Vitek MP, Bennett ER, Sullivan PM, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem 2003; 278: 48529-33.
8. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
10. Høgh P, Oturai A, Schreiber K, Blinkenberg M, Jørgensen OS, Ryder L, et al. Apolipoprotein E and multiple sclerosis: impact of the epsilon-4 allele on susceptibility, clinical type and progression rate. Mult Scler 2000; 6: 226-30.
11. Zivelin A, Rosenberg N, Peretz H, Amit Y, Kornbrot N, Selighson U. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin Chem 1997; 43: 1657-59.
12. Santos M, Costa MDC, Rio ME, Sá MJ, Monteiro M, Valenca A, et al. Genotypes at the Apo E and SCA2 loci do not predict the course of multiple sclerosis in patients of Portuguese origin. Mult Scler 2004; 10: 153-57.
13. Kantarci OH, Hebrink DD, Achenbach SJ, Pittock SJ, Altintas A, Schaefer-Klein JL, et al. Association of APOE polymorphisms with disease severity in MS is limited to women. Neurology 2004; 62: 811-14.
14. Savettieri G, Messina D, Andreoli V, Bonavita S, Caltagirone C, Cittadella R, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol 2004; 251: 1208-14.
15. Weatherby SJ, Mann CI, Fryer AA, Strange RC, Hawkins CP. No association between the APOE E4 allele and outcome and susceptibility in primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68: 532.
16. Weatherby SJ, Mann CL, Davies MB, Carthy D, Fryer AA, Boggild MD, et al. Polymorphisms of apolipoprotein E; outcome and susceptibility in multiple sclerosis. Mult Scler 2000; 6: 32-36.
17. Niino M, Kikuchi S, Fukazawa T, Yabe I, Tashiro K, et al. Polymorphisms of apolipoprotein E and Japanese patients with multiple sclerosis. Mult Scler 2003; 9: 382-86.
18. Ballerini C, Campani D, Rombolà G, Gran B, Nacmias B, Amato MP, et al. Association of apolipoprotein E polymorphism to clinical heterogeneity of multiple sclerosis. Neurosci Lett 2000; 296: 174-76.
19. Carlin C, Murray L, Graham D, Doyle D, Nicoll J. Involvement of Apolipoprotein E in multiple sclerosis: absence of remyelination associated with possession of the APOE E2 allele. J Neuropathol Exper Neurol 2000; 59: 361-67.
20. Chapman J, Sylantiev C, Nisipeanu P, Korczyn AD. Preliminary observations on APOE E4 allele and progression of disability in multiple sclerosis. Arch Neurol 1999; 56: 1484-87.
21. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, et al. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology 2001; 56: 312-16.
22. Enzinger C, Ropele S, Strasser-Fuchs S, Kapeller P, Schmidt H, Poltrum B, et al. Lower levels of N-acetulaspartate in multiple sclerosis patients with the apolipoprotein E E4 allele. Acta Neurol 2003; 60: 65-70.
23. Evangelou N, Jackson M, Beeson D, Palace J. Association of the APOE E4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999; 67: 203-205.
24. Fazekas F, Strasser-Fuchs S, Kollegger H, Berger T, Kristoferitsch W, Schmidt H, et al. Apolipoprotein E E4 is associated with rapid progression of multiple sclerosis. Neurology 2001; 57: 853-57.
25. Ferri C, Sciacca FL, Veglia F, Martinelli F, Comi G, Canal N, et al. ApoE E2-4 and -491 polymorphisms are not associated with MS. Neurology 1999; 53: 888-89.
26. Gervais A, Gaillard O, Plassart E, Reboul J, Fontaine B, Schuller E. Apolipoprotein E polymorphism in multiple sclerosis. Ann Clin Biochem 1998; 35: 135-36.
27. Oliveri RL, Cittadella R, Sibilia G, Manna I, Valentino P, Gambardella A, et al. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand 1999; 100: 290-95.
28. Pirttilä T, Haanpää M, Mehta PD, Lehtimaki T. Apolipoprotein E (APOE) phenotype and APOE concentrations in multiple sclerosis and acute herpes zoster. Acta Neurol Scand 2000; 102: 94-98.
29. Rubinsztein DC, Hanlon CS, Irving RM, Goodburn S, Evans DGR, Kellar-Wood H, et al. Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease. Mol Cell Probes 1994; 8: 519-25.
30. Savettieri G, Andreoli V, Bonavita S, Cittadella R, Caltagirone C, Fazio MC, et al. Apolipoprotein E genotype does not influence the progression of multiple sclerosis. J Neurol 2003; 250: 1094-1098.
31. Zakrzewska-Pniewska B, Styczynska M, Podlecka A, Samocka R, Peplonska B, Barcikowska M, et al. Association of apolipoprotein E and myeloperoxidase genotypes to clinical course of familial and sporadic multiple sclerosis. Mult Scler 2004; 10: 266-71.
32. Zwemmer JNP, Van Veen T, Van Winsen L, Van Kamp GJ, Barkhof F, Polman CH, et al. No major association of Apo E genotype with disease characteristics and MRI findings in multiple sclerosis. Mult Scler 2004; 10: 272-77.
33. Schmidt S, Barcellos LF, DeSombre K, Rimmler JB, Lincoln RR, Bucher P, et al. Association of polymorphisms in the apolipoprotein E region to and progression of multiple sclerosis. Am J Hum Genet 2002; 70: 708-17.
34. Masterman T, Zhang Z, Hellgren D, Salter H, Anvret M, Lilius L, et al. ApoE genotypes and disease severity in multiple sclerosis. Mult Scler 2002; 8: 98-103.
35. Enzinger C, Ropele S, Smith S, Phil D, Strasser-Fuchs S, Poltrum B, et al. Accelerated evolution of brain atrophy and 'black holes' in MS patients with Apo E-E4. Ann Neurol 2004; 55: 563-69.
36. Fazekas F, Strasser-Fuchs S, Schmidt H, Enzinger C, Ropele S, Lechner A, et al. Apolipoprotein E genotype related differences in brain lesions of multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 69: 25-28.
37. Schreiber K, Oturai AB, Ryder LP, Madsen HO, Jørgensen OS, Svejgaard, A et al. Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRBI*1501, CCR5 deletion mutation, apolipoprotein E). Mult Scler 2002; 8: 295-98.
38. Stefano ND, Bartolozzi ML, Nacmias B, Zipoli V, Mortilla M, Guidi L, et al. Influence of apolipoprotein E E4 genotype on brain tissue integrity in relapsing-remitting multiple sclerosis. Arch Neurol 2004; 61: 536-40.
39. Lazo M, Alonso ME, Corona T. Apo E genotype and idiopathic optic neuritis. Mult Scler 2003; 9: P241 (abstract).